Screener
Supernus Pharmaceuticals SUPN Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Prepaid expenses and other assets | (12,432) | 7,372 |
| Accrued product returns and rebates | 28,623 | 1,428 |
| Accounts payable and other liabilities | 49 | 3,938 |
| Net cash provided by operating activities | 66,524 | 30,599 |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (78,438) | (118,557) |
| Maturities of marketable securities | 59,220 | 156,201 |
| Purchases of property and equipment | — | (327) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's operating cash flow?
- Supernus Pharmaceuticals (SUPN) reported operating cash flow of $66.52M in Q1 2026.
- How has Supernus Pharmaceuticals's operating cash flow changed year-over-year?
- Supernus Pharmaceuticals's operating cash flow increased by 117.4% year-over-year, from $30.6M to $66.52M.
- What is the long-term trend for Supernus Pharmaceuticals's operating cash flow?
- Over 2 years (2021 to 2024), Supernus Pharmaceuticals's operating cash flow has grown at a 14.5% compound annual growth rate (CAGR), from $131.24M to $171.95M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Supernus Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude